46. Wald, Nicholas J. and Morris, Joan K… 2003. Teleoanalysis: combining data from different types of study. BMJ, 327, 616–618.

47. The Times (Public Agenda), 6 March 2007.

48. Smith, Richard, 2003. Editor’s choice: The screening industry. BMJ, 326,26 April 2003.

49. Lechin, Fuard and others, 2002. N euro circuitry and Neuroauto-nomic Disorders. Karger.

50. Gottlieb, Scott, 2003. US drug sales continue to rise. BMJ, 326, 518.

51. Gottlieb, Scott, 2002. Drug companies maintain ‘astounding’ profits, BMJ, 324, 1054.

52. Kjaergard, Lise L. and Als-Nielsen, Bodily 2002. Association between competing interests and authors’ conclusions: epide-miological study of randomised clinical trials published in the BMJ. BMJ, 325, 249–252.

53. Eaton, Lynn, 2003. Readers want transparency in link between doctors an drug firms. BMJ, 326, 1352.

54. Mayor, Susan, 2002. Researchers claim clinical trials are reported with misleading statistics. BMJ, 324, 1353.

55. JAMA, 2003, 389, 454–465, quoted by Hopkins Tanne, Janice, 2003. Industry is deeply involved in funding US research. BMJ, 326, 179.

56. Tonks, Alison, 2002. Authors of guidelines have strong links with drugs industry. BMJ, 324, 383.

57. Spurgeon, David, 2002. Doctors accept $50 a time to listen to drug representatives. BMJ, 324, 1113.

58. Gottlieb, Scott, 2003. A fifth of Americans contact their doctor as a result of direct to consumer drug advertising. BMJ, 325, 854.

59. BMJ, 2003. Drug companies want to inform patients. BMJ, 326, 1286.

60. Watson, Rory, 2003. EU health ministers reject proposal for limited direct to consumer advertising. BMJ, 326, 1284.

61. Watson, R., 2006. Cancer group denies company funding will influence its agenda. BMJ, 333, 874.

62. Mayor, Susan, 2002. GMC issues new guidance on clinical research. BMJ, 324,384.

63. Marwick, Charles, 2002. US tackles drug company gifts to doctors. BMJ, 325, 795.

64. Mosconi, Paola, 2003. Declaration of competing interests is rare in Italian breast cancer associations. BMJ, 327, 344.

65. Herxheimer, A., 2003. Relationships between the pharmaceutical industry and patients’ organisations. BMJ, 326, 1208–1210.

66. Hirst, J., 2003. Charities and patient groups should declare interests. BMJ, 326, 1211.

67. Clark, Jocalyn, 2003. A hot flush for Big Pharma. BMJ, 327, 400.

68. Writing Group for the Women’s Health Initiative Investigators, 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288, 321–333.

69. The Times, 15 December 2006.

70. Moynihan, Ray, 2003. US seniors group attacks pharmaceutical industry ‘fronts’. BMJ, 326, 351.

71. Cho, E, and others, 2006. Red meat intake and risk of breast cancer among premenopausal women. Archives of International Medicine, 166, 2253–2259.

72. Lenzer, Jeanne, 2002. The operation was a success (but the patient died). BMJ, 325, 664.

73. Moynihan, Ray, 2003. Blurring the boundaries. BMJ. 326, 1094.

74. The selling of a wonder drug. The Guardian, 29 March 2006.

75. http://en.wikipedia.org/wiki/Trastuzumab.

76. Barrett, A. and others, 2006. How much will Herceptin really cost? BMJ, 333, 118–120.

77. Bartlett, Christopher, Sterne, Jonathan and Egger, Matthias, 2002. What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers. BMJ, 325,

81.

78.http://www.public.asu.edu/!! tadams2/Quotes/Ambulance

79. www.cancersupportinternational.com

80. Campbell, T, Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Ben-bella Books.

81. Robbins, John, 1987. A Diet for a New America. Stillpoint.

82. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.